Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Special populations and label explansion studies with the fixed does combinations artemether-lumefantrine, amodiaquine-artesunate, and dihydroartemisinin-piperaquine in Zambia, Malawi and Mozambique.

Next Previous
Trial Profile

Special populations and label explansion studies with the fixed does combinations artemether-lumefantrine, amodiaquine-artesunate, and dihydroartemisinin-piperaquine in Zambia, Malawi and Mozambique.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jan 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 27 Aug 2018 Results published in the Antimicrobial Agents and Chemotherapy
  • 14 May 2018 Results from 2 studies (PACTR2010030001871293, n=18 and PACTR2010030001971409, n=75) assessing pharmacokinetics and safety profiles published in the Antimicrobial Agents and Chemotherapy
  • 08 May 2013 Status changed from not yet recruiting to completed as reported by Pan-African Clinical Trials Registry.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top